poisar

Stocks · News reference

ProMIS Neurosciences Q2 EPS $(1.28) Beats $(1.38) Estimate

Benzinga Newsdesk

ProMIS Neurosciences (NASDAQ:PMN) reported quarterly losses of $(1.28) per share which beat the analyst consensus estimate of $(1.38) by 7.25 percent. This is a 82.34 percent increase over losses of $(7.25) per share

More stocks newsConnected markets

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

PMN
Source
benzinga
Observed
Checked
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading

  1. Delveinsight

    Alzheimer's Disease Clinical Trial and Competitive Landscape Enters a New Phase as 200+ Companies Advance Clinical Programs | DelveInsight

    Over 200 companies are advancing more than 240 pipeline Alzheimer's disease therapies across various clinical development stages. The market is being driven by an aging population, rising disease prevalence, and the emergence of disease-modifying therapies that enable earlier intervention and biomarker-guided care. Two therapies have recently received FDA approval: KISUNLA (donanemab) from Eli Lilly and LEQEMBI (lecanemab-irmb) from Eisai/Biogen, both targeting amyloid plaques to slow disease progression.

    LLYBIIBJNJABBVRHHBY
  4. SEC EDGAR

    8-K filing — ProMIS Neurosciences Inc. (PMN)

    Filed: 2026-08-13 AccNo: 0001104659-26-095905 Size: 246 KB Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits

    PMN